– USA, NH – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader today announced the appointments of Dana Brown and Tim Irish to its Board as Independent Directors, effective January 10, 2022.
“We are pleased to welcome Ms. Brown and Prof. Irish to the Board as they each offer tremendous insight and decades of relevant experience in corporate leadership, brand stewardship, and health technologies, along with a proven track record of leading innovation and strategic change. With Ms. Brown’s experience in technology and women’s breast health, and Prof. Irish’s global expertise, these appointments will offer our Company unique and fresh perspectives in areas that stand to benefit both the Detection and Therapy sides of our business, while also underscoring the Company’s commitment to increasing shareholder value,” said President and incoming CEO, Stacey Stevens.
The Company also announced the addition of Stacey Stevens, President, and incoming CEO to its Board of Directors, bringing the total number of Board members to eight.
About Dana Brown
A 30-year technology industry veteran, Ms. Brown is currently the SVP, Chief Strategy and Operations Officer at Susan G. Komen, the world’s leading nonprofit breast cancer organization supporting millions of people in the U.S. and countries worldwide by advocating for patients, driving research breakthroughs, improving access to high-quality care, offering direct patient support and empowering people with trustworthy information. Before that role, she served as SVP and Chief Digital Officer at United Way Worldwide. Ms. Brown was also a founding team member of multiple successful ventures including co-founder and CMO for MetaSolv Software, CEO of Ipsum Networks, and spent the early years of her career at Texas Instruments and Arthur Andersen.
“iCAD’s commitment to delivering innovative AI-based breast cancer detection and therapy capabilities that improve the patient experience and clinical decision support for providers is to be commended and I look forward to working with the team, who is equally as passionate about improving women’s health and optimizing outcomes for patients. t is an honor to join iCAD’s Board of Directors, and to be a part of this values-led company that is laser-focused on innovation and growth,” said Ms. Brown.
About Pr. Timothy Norris Irish
An experienced leader in the life sciences and healthcare sectors, Professor Timothy Norris Irish is currently a Professor at the Business School at King’s College London. He also is currently a Trustee of Picker Institute Europe and a Committee member of the Alzheimer’s Society, in addition to several other remunerated Board roles at KHP Medtech Innovations, Team Consulting Ltd., ImaginAb Inc, eZono AG, Feedback Plc, and Deltex Medical Group Plc. Prof. Irish also recently served as Vice-Chair at the National Institute for Health and Care Excellence, where he previously held the roles of Acting Chair and Independent Director.
“As a global company with a well-established portfolio of products currently available across the U.S. and more than 15 countries outside the U.S., iCAD’s technology is already making a positive impact on the lives of many patients worldwide. I am honored to join iCAD’s Board of Directors and look forward to working with the team to help drive the adoption of the Company’s leading-edge technologies that are addressing some of the most urgent and complex challenges in healthcare today,” said Prof. Irish.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
For more information: https://www.icadmed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
